PP
ALT icon

PDT Partners’s Altimmune ALT Stock Holding History

PDT Partners’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,915
Closed -$216K – 621
2022
Q3 		$216K Sell
16,915
-39,351
-70% -$581K 0.03% 691
2022
Q2 		$658K Sell
56,266
-68,111
-55% -$420K 0.06% 524
2022
Q1 		$757K Buy
124,377
+5,501
+5% +$40.5K 0.07% 464
2021
Q4 		$1.09M Buy
+118,876
New +$1.26M 0.08% 346

Other funds holding ALT

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PDT Partners's ALT Position: Q4 2022 in Review

PDT Partners sold out of Altimmune (ALT) in Q4 2022, closing a stake of 16,915 shares — an estimated $216K sold.

PDT Partners first reported a position in ALT in Q4 2021 and held it in 4 quarters. The position peaked at $1.09M in Q4 2021. 128 funds tracked by Wall St. Rank hold ALT as of Q4 2022.

  • PDT Partners reported no remaining Altimmune position as of Q4 2022 after selling out during the quarter.
  • PDT Partners sold 16,915 Altimmune shares in Q4 2022, an estimated $216K.
  • PDT Partners first reported a position in Altimmune in Q4 2021 and held it in 4 quarters.
  • PDT Partners's Altimmune position peaked at $1.09M in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Altimmune as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.